Change from baseline to end of week 12 in haemodynamic variables in the subgroup of patients with PAH-CHD in Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (observed values)
| Placebo | Riociguat 2.5 mg–maximum | Riociguat 1.5 mg–maximum | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Baseline | Change from baseline | n | Baseline | Change from baseline | n | Baseline | Change from baseline | |
| PVR (dyn·s/cm5) | 11 | 1312±763 | −66±632 | 13 | 1130±664 | −250±410 | 7 | 1047±564 | −126±368 |
| mPAP (mm Hg) | 11 | 61±23 | +1±8 | 14 | 59±21 | −4±7 | 7 | 67±19 | −3±10 |
| Cardiac index (L/min/m2) | 11 | 2.2±0.6 | +0.2±0.7 | 13 | 2.6±0.6 | +0.4±0.6 | 7 | 3.3±1.4 | +0.3±1.2 |
| Right atrial pressure (mm Hg) | 10 | 8.1±6.0 | +2.7±6.4 | 14 | 8.4±5.3 | −0.3±4.3 | 7 | 9.7±3.1 | −1.7±2.8 |
| Mean arterial pressure (mm Hg) | 12 | 90±9 | −3±8 | 14 | 82±13 | −7±9 | 7 | 92±21 | −9±9 |
| Systemic vascular resistance (dyn·s/cm5) | 10 | 1995±394 | −287±587 | 13 | 1516±376 | −307±326 | 7 | 1388±398 | −278±472 |
| Mixed venous oxygen saturation (%) | 11 | 62±10 | −3±7 | 13 | 69±8 | +2±6 | 7 | 68±7 | +1±6 |
Data are mean±SD.
CHD, congenital heart disease; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance.